Fludarabine
Tumor Skin
Obsidian Therapeutics, Inc.Small moleculePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Tumor Skin cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
gsk1120212 TriHealth Inc. | Phase 2 | CCC |
Dabrafenib TriHealth Inc. | Phase 2 | CCC |
ICP34.5-, ICP47-DELETED HERPES SIMPLEX VIRUS 1 (HSV-1) INCORPORATING THE HUMAN GM-CSF GENE TriHealth Inc. | Phase 2 | CCC |
Acetazolamide Obsidian Therapeutics, Inc. | Phase 1/2 | CCC |
Obx-115 Obsidian Therapeutics, Inc. | Phase 1/2 | CCC |
Oxygen West Virginia University | N/A | D |
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →